Prior to the FDA, Dr. Lynch has had about 15 years experience as a research scientist in various capacities in the public, academic and private sectors; his primary scientific interests have been in the areas of protein chemistry and enzymology.
Dr. Lynch received his Bachelor of Arts degree in biology from American International College and his Masters in biology from Clark University. Dr. Lynch received his Ph.D. in biology from Wayne State University and his J.D. from Georgetown University Law Center, where he graduated cum laude.
Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical hemostats. Haemacure's lead product candidate,
Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III
clinical trials during the first half of 2009. Haemacure's second product
candidate is thrombin, a component of its fibrin sealant, now in
preclinical stage. Follow-on development will focus on the use of its
fibrin sealant in adhesion prevention, aesthetics, combination with
biomaterials, drug delivery, regenerative medicine, skin graft fixation for
burn injuries and wound management. Haemacure has discovered eleven
additional specialty proteins and enzymes in one if its two plasma
fractions and seeks to advance these proteins and enzymes through
partnerships with pharmaceutical and biotechnology companies. Haemacure is
headquartered in Montreal, Quebec and operates offices in Sarasota, Florida
through a w
|SOURCE HAEMACURE CORPORATION|
Copyright©2008 PR Newswire.
All rights reserved